TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05589012

Intervention type: BIOLOGICAL
Intervention: Cell line and virus
Description: C6/36 cells will be cultured in L15 culture medium (Leibovitz's L-15 medium), supplemented with 5% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin at 28°C in a humidified atmosphere containing 5% C02. ZIKV and TONV will be expanded and titrated using C6/36 cells. The viral stock will be aliquoted in 100 µL aliquots and stored at -80°C.

Intervention type: BIOLOGICAL
Intervention: Infection of human placental culture explants
Description: Placental tissues will be handled within one hour of delivery. The chorionic villi will be dissected into 5mm sections and the tissues washed abundantly, minimum 3 times with a standard culture medium (RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% L-Glutamine and 1% Penicillin/Streptomycin) to remove maternal blood, membranes and blood clots.~Collagen gel sponges will be placed in 6-well plate wells containing 3mL of culture medium (RPMI-1640 supplemented with 15% heat-inactivated fetal bovine serum (FCS), 1% Penicillin/streptomycin, 0 1% Gentamycin, 1% Amphotericin B, 1% L-Glutamine, 1% non-essential amino acid, 1% sodium pyruvate) per well. Chorionic villi will be dissected into 5mm sections and placed on top of collagen gel sponges at the interface between culture medium and air.

Intervention type: BIOLOGICAL
Intervention: Determination of viral load in tissues by qRT-PCR
Description: The tissues will be lysed by mechanical disruption in a lysis buffer + 4%TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) (Machery-Nagel ref: 740395.107) with the Precellys system. The lysed tissues will be diluted in 100 mg/mL of Macherey-Nagel lysis buffer, aliquoted and stored at -80°C until extraction. Total RNA will be extracted in duplicate using the Nucleospin 96 RNA Core kit (Macherey Nagel ref: 740466.4), following the supplier's instructions.~Standard samples, controls and ZIKV and TONV viral RNA will be extracted and tested in parallel under the same conditions. The extracted RNA will be subjected to reverse transcriptase, using the Superscript One-Step RT-qPCR kit (Invitrogen ref: 11732088) according to the manufacturer's recommendations, with a probe and primer specific for ZIKV and TONV.
Study: NCT06373900

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wound closure
Description: Group A wound will be closed with Polypropylene and Group B wound will be closed with Polyglactin 910 suture. both wound closure followed for healing, infection and scar formation till 30th post operative day.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wound closure
Description: Group A wound will be closed with Polypropylene and Group B wound will be closed with Polyglactin 910 suture. both wound closure followed for healing, infection and scar formation till 30th post operative day.
Study: NCT06301776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: To compare the safety and efficacy of different DAPT duration combined with ticagrelor monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: To compare the safety and efficacy of different DAPT duration combined with ticagrelor monotherapy.
Study: NCT05453071

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Exercise Therapy Approach (BETY)
Description: BETY, based on function-oriented core stabilization exercises, will be applied in patients with systemic sclerosis. This exercise model includes pain management strategies, dance therapy-authentic movement. Function-oriented core stabilization exercises have the feature of being made difficult against gravity according to the person's ability to do. Initial exercises start from the stage where the distal segment of the extremity is on the ground, called closed-kinetic. This level, which is quite easy, becomes more difficult following the success of the individual. It can be started from the mat level and progressed by modifying it with theraband and exercise ball. It is used at the beginning and end of dance therapy and authentic movement sessions. In the session, cognitive restructuring technique is used to break the vicious cycle of pain-emotional-spasm during exercise. This exercise model is the main rehabilitation approach of the Rheumatological Rehabilitation Unit.
Study: NCT05687253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BX1000
Description: IV BX1000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BX1000
Description: IV BX1000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BX1000
Description: IV BX1000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium Bromide
Description: IV Rocuronium
Study: NCT06104670

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synaquell(TM)
Description: 7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
Study: NCT04178434

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based CBT intervention
Description: A nine step intervention including internet-based feedback by psychologists
Study: NCT04851327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Energy preload
Description: Tests the extent to which participants reduce their intake at a meal following ingestion of a high energy preload drink

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low energy preload
Description: Tests the amount participants eat at a meal following ingestion of a low energy preload drink

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Test meal to follow low or high energy preload

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Test meal to follow low or high energy preload
Study: NCT05399160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Supportive Care
Description: Nurse-led supportive care was given to women who had breast surgery and planned to receive chemotherapy. Nurse-led supportive care was applied to women for eight weeks in the form of face-to-face clinic and telephone interviews.It took an average of 30 minutes to interview women with breast cancer at the clinic, and 15 minutes on average by phone.
Study: NCT06227572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CATNAP MI
Description: Three motivational interviewing (MI) sessions will be facilitated by trained MI staff and will focus on improving participants' knowledge about their OSA diagnosis, understanding of sleep health, and increasing PAP use. Sessions will also provide information about health benefits associated with good sleep and will help participants create an action plan regarding their PAP use and indicators of success, when appropriate.~Electronic messaging will be standardized for frequency and content but personalized to participants' preferred mode of delivery. Messages will focus on PAP adherence or non-adherence.
Study: NCT05708729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCS surgery for CPSP
Description: The investigational devices that will be used for the MCS surgeries are the following: the Vanta with AdaptiveStim Technology Primary cell neurostimulator or the Intellis Implantable Neurostimulator with AdaptiveStim Technology from Medtronic, Inc. (MN, USA). These implantable neurostimulators are intended to generate electrical pulses and to deliver stimulation trough one or more leads as part of a neurostimulation system for pain therapy in adults.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCS surgery for CPSP
Description: The investigational devices that will be used for the MCS surgeries are the following: the Vanta with AdaptiveStim Technology Primary cell neurostimulator or the Intellis Implantable Neurostimulator with AdaptiveStim Technology from Medtronic, Inc. (MN, USA). These implantable neurostimulators are intended to generate electrical pulses and to deliver stimulation trough one or more leads as part of a neurostimulation system for pain therapy in adults.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vc-DBS surgery for CPSP
Description: For the deep brain stimulation procedure, we will use Vercise stimulators from Boston Scientific together with the Cartesia Directional Leads or the Percept PC stimulator from Medtronic.
Study: NCT05565794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Intake of up to 3 tablets of pemigatinib (4,5 mg each) daily per oral for 14 days in a 21-day cycle (maximum of 18 cycles in total)
Study: NCT05427201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive brain stimulation technique designed to alter network function

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: ACT is a mindfulness-based cognitive behavioral intervention that has demonstrated efficacy for chronic pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: ACT is a mindfulness-based cognitive behavioral intervention that has demonstrated efficacy for chronic pain.
Study: NCT05214105

Intervention type: OTHER
Intervention: Biospecimen/DNA collection and analysis
Description: Patients will be followed longitudinally with collection of CBC and chemistries as well as research biomarkers (urine, plasma, and genomic materials).
Study: NCT04953936

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB-enriched Nutritional Supplements
Description: The participants will receive oral HMB-enriched nutritional supplements (65 g, once daily), which include soybean isolate protein, flaxseed oil powder, yam powder, whey protein, oligomeric isomaltose powder, cocoa powder, medium-chain fatty acid powder, calcium beta-hydroxy-beta-methylbutyrate, sunflower seed oil powder, L-glutamine, wheat germ powder, membrane isolated casein, wheat oligopeptide, konjac flour, vitamin E, vitamin D, stevioside, edible flavors.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (maltodextrin 65 g once daily) with the same package as the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Restrition Diet
Description: Caloric restriction diet with individualized nutritional guidance from professional dietitians by video regarding caloric restriction strategies

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Caloric Restrition Diet
Description: Caloric restriction diet with individualized nutritional guidance from professional dietitians by video regarding caloric restriction strategies
Study: NCT06049810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112
Description: Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& Dose 1 IBI112 through week 44

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IBI112/placebo
Description: Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& placebo through week 44 by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IBI112/placebo
Description: Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& placebo through week 44

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112
Description: Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& Dose 1 IBI112 through week 44

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112
Description: Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 through week 44

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112
Description: Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 through week 44 by subcutaneous injection
Study: NCT06628947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Sterile Saline)
Description: A control 50 μl injection of clear sterile saline liquid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Sterile Saline)
Description: A control 50 μl injection of clear sterile saline liquid
Study: NCT06104670

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
Study: NCT05300620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Foot Orthotics EVA
Description: these are custom foot orthotics made out of Ethyl Vinyl Acetate material

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Original Liner
Description: these are original shoe liners

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Foot Orthotics PU
Description: these are custom foot orthotics made out of Expanded Poly Urethane Material

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Hybrid Foot Orthotics
Description: these are custom foot orthotics made out of a combination of Ethyl Vinyl Acetate and Expanded Poly Urethane Material
Study: NCT05021991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg PRAX-944
Description: Once daily oral treatment with titration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg PRAX-944
Description: Once daily oral treatment with titration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 100 mg PRAX-944
Description: Once daily oral treatment with titration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg PRAX-944
Description: Once daily oral treatment with titration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg PRAX-944
Description: Once daily oral treatment with titration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 60 mg PRAX-944
Description: Once daily oral treatment with titration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily oral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily oral treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily oral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flexibly dosed 20 mg to 100 mg PRAX-944
Description: Once daily oral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flexibly dosed 20 mg to 100 mg PRAX-944
Description: Once daily oral treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flexibly dosed 20 mg to 100 mg PRAX-944
Description: Once daily oral treatment
Study: NCT05163444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait analysis with rolling cane
Description: 6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gait analysis with quadripod cane
Description: 6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
Study: NCT06011057

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum C reactive protein (CRP) level
Description: An immunoturbidimetric method using a Modular P Analyzer will be used to carry out HSCRP assay, with a quantitation limit of 0.5 mg/L.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum C reactive protein (CRP) level
Description: An immunoturbidimetric method using a Modular P Analyzer will be used to carry out HSCRP assay, with a quantitation limit of 0.5 mg/L.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: All examinations will be carried out by an experience operator with a transvaginal probe on high-resolution ultrasound machines. Pregnancies will be dated from the LMP. Other measurements will be obtained during the scan as the mean gestation sac diameter, volume of the gestation sac and the embryonic heart rate (FHR).

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: All examinations will be carried out by an experience operator with a transvaginal probe on high-resolution ultrasound machines. Pregnancies will be dated from the LMP. Other measurements will be obtained during the scan as the mean gestation sac diameter, volume of the gestation sac and the embryonic heart rate (FHR).
Study: NCT06111300

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Group D (dexmedetomidine group): Patients in this group will receive loading dose of dexmedetomidine 0.7 ug/kg over 10 min. then maintenance dose 0.2 - 1 ug/kg/hr till end of surgery. Group C (control group): Patients in this group will receive volum- matched normal saline infusion (NaCL 0.9%) as a placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Group D (dexmedetomidine group): Patients in this group will receive loading dose of dexmedetomidine 0.7 ug/kg over 10 min. then maintenance dose 0.2 - 1 ug/kg/hr till end of surgery. Group C (control group): Patients in this group will receive volum- matched normal saline infusion (NaCL 0.9%) as a placebo.
Study: NCT05577442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy
Description: Trastuzumab (8-6mg/3weekly)，Pyrotinib（320mg/day）Dalpiciclib（125mg/day，With three weeks separated by one week）
Study: NCT06025097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Solution
Description: Methyl Prednisone (Trade name: SOLU-MEDROL) + Platelet rich Plasma (Autologous Biological product) via intra-tympanic rout about 1-1.5 ml.
Study: NCT06364098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 microgram of misoprostol given either sublingually or intrauterine during CS after placental removal together with IV oxytocin infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 microgram of misoprostol given either sublingually or intrauterine during CS after placental removal together with IV oxytocin infusion
Study: NCT04807790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation based structured home program applications
Description: The structured home program will consist of activities determined by the family members according to the functional level of the child and the activities he / she can not do, and which are determined according to the goals specific to the child. In order to ensure that the structured home program created can be implemented by the family, a 1 hour family training will be provided.~After the structured home program training, a 45-minute video interview will be held with one of the family members (mother-father-caregiver) once a week, in order to check by the physiotherapist whether the home program is implemented correctly. Video interviews will be the telerehabilitation part of the study.
Study: NCT05315973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testing sensor vs glucometer
Description: Will test accuracy of this sensor; there will be no intervention.
Study: NCT05135182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Description: Furazolidone-tetracycline-containing quadruple regimens

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: metronidazole-tetracycline-containing quadruple regimens
Study: NCT05933993

Intervention type: OTHER
Intervention: Elective cesarean section
Description: The study does not contain an intervention in itself, but women are included if they undergo an elective cesarean section
Study: NCT05894486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium[177Lu] Oxodotreotide Injection
Description: Lutetium\[177Lu\] Oxodotreotide InjectionFour administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity
Study: NCT06000800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B
Description: Umbilical cord clamping at 30 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group C
Description: Umbilical cord clamping at 60 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group D
Description: Umbilical cord clamping at 90 seconds
Study: NCT05744830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overdenture
Description: 15 patients will receive removable complete dentures, then a single implant is placed in the midline of the mandible, then loaded with the denture.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complete Denture
Description: 15 patients will only receive removable complete dentures
Study: NCT06000800

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group A
Description: Umbilical cord clamping immediately after birth (5 second)
Study: NCT05381532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled sleep
Description: Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment.
Study: NCT06257615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education provided via TeleNursing
Description: Online Video Call Online video interviews were conducted with the patients in the intervention group once in the first week (day 1-7), once in the second week (day 8-14) and once in the third week, using mobile phone programs and/or computer programs that provide video conversation opportunities. It was conducted in the form of remote online video calls, held three times in total, once within the 15-21st day.~Voice Phone Call After audio telephone interviews and online video interviews were completed within the first three weeks after the patients in the intervention group were discharged; It was carried out using a mobile phone 3 times in total: once in the fourth week (day 22-28), once in the fifth week (day 29-35) and once in the sixth week (day 36-42).
Study: NCT05381532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled sleep
Description: Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled sleep
Description: Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled sleep
Description: Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment.